Hospital Clinico Universitario de Salamanca
Hospital Clinico Universitario de Salamanca
Salamanca, Spain30 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-10-09 | NCT06585774 | |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Recruiting | Phase 3 | 2026-10-08 | NCT07623200 | |
| Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy | Invasive Mould Infection | Recruiting | Phase 2 | 2026-10-05 | NCT07215273 | |
| A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-09-30 | NCT04980222 | |
| A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-09-25 | NCT07054190 | |
| A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Phase 1 | 2026-09-18 | NCT07220564 | |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, heart disorder, heart failure, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-09-16 | NCT07037459 | |
| Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-09-11 | NCT07555938 | |
| A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04680052 | |
| Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 3 | 2026-09-03 | NCT06465953 | |
| A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-09-03 | NCT04873362 | |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT06821542 | |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Alzheimer disease, Amyloid Neuropathies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, amyloidosis, brain disorder, cardiomyopathy, cardiovascular disorder, central nervous system disorder, cognitive disorder, dementia, familial amyloid neuropathy, heart disorder, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, proteostasis deficiencies, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-08-04 | NCT06563895 | |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-07-22 | NCT04404283 | |
| Sequent Extended Study | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Not stated | 2026-07-15 | NCT05788432 | |
| Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial | Arterial Occlusive Diseases, Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, ST-elevation myocardial infarction, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2026-07-15 | NCT05599061 | |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-07-09 | NCT02319837 | |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-06-25 | NCT04509700 | |
| A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 2 | 2026-06-16 | NCT04710576 | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, diffuse large B-cell lymphoma, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-06-10 | NCT04844866 | |
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-05-22 | NCT06388564 | |
| A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment | Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria | Active, not recruiting | Phase 3 | 2026-04-30 | NCT05133531 | |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-04-30 | NCT04608318 | |
| Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-04-20 | NCT03761108 | |
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-04-13 | NCT05955508 |